Upadacitinib Beats Dupilumab Across All Ranked Secondary End Points in AD Study: Dr. Jonathan Silverberg Reviews the Data
Jonathan Silverberg, MD, PhD, MPH, Director of Clinical Research at The George Washington University School of Medicine and Health Sciences in Washington, DC, breaks down the new data from LEVEL-UP, a head-to-head study evaluating upadacitinib (Rinvoq, AbbVie) vs. dupilumab (Dupixent, Sanofi & Regeneron) for the treatment of adolescents and adults with moderate to severe atopic […]